Show simple item record

Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer

dc.contributor.authorRicco Pacheco, Natalia
dc.contributor.authorFlor, Amy
dc.contributor.authorWolfgeher, Donald
dc.contributor.authorEfimova, Elena V.
dc.contributor.authorRamamurthy, Aishwarya
dc.contributor.authorAppelbe, Oliver K.
dc.contributor.authorBrinkman, Jacqueline
dc.contributor.authorTruman, Andrew W.
dc.contributor.authorSpiotto, Michael T.
dc.contributor.authorKron, Stephen J.
dc.date.accessioned2020-01-04T17:24:59Z
dc.date.available2020-01-04T17:24:59Z
dc.date.issued2019-06-21
dc.identifier.citationRicco, Natalia; Flor, Amy; Wolfgeher, Don [et al.]. Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer. Molecular Oncology, vol. 13, núm. 9, p. 1927-1943. Disponible en: <https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.12535>. Fecha de acceso: 4 ene. 2020. DOI: 10.1002/1878-0261.12535ca
dc.identifier.issn1878-0261ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/1419
dc.description.abstractRadioresistance is a major hurdle in the treatment of head and neck squamous cell carcinoma (HNSCC). Here, we report that concomitant treatment of HNSCCs with radiotherapy and mevalonate pathway inhibitors (statins) may overcome resistance. Proteomic profiling and comparison of radioresistant to radiosensitive HNSCCs revealed differential regulation of the mevalonate biosynthetic pathway. Consistent with this finding, inhibition of the mevalonate pathway by pitavastatin sensitized radioresistant SQ20B cells to ionizing radiation and reduced their clonogenic potential. Overall, this study reinforces the view that the mevalonate pathway is a promising therapeutic target in radioresistant HNSCCs.ca
dc.format.extent17ca
dc.language.isoengca
dc.publisherWileyca
dc.relation.ispartofMolecular Oncologyca
dc.relation.ispartofseries13;9
dc.rights© 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. 1927. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.ca
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.otherADN--Anàlisica
dc.subject.otherRadiació
dc.subject.otherEstatines (Medicaments cardiovasculars)
dc.subject.otherRadioteràpia
dc.subject.otherADN--Análisis
dc.subject.otherRadiación
dc.subject.otherEstatinas
dc.subject.otherRadioterapia
dc.subject.otherDNA--Analysis
dc.subject.otherRadiation
dc.subject.otherStatins (Cardiovascular agents)
dc.subject.otherRadiotherapy
dc.titleMevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancerca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/acceptedVersionca
dc.embargo.termscapca
dc.subject.udc61ca
dc.identifier.doihttps://dx.doi.org/10.1002/1878-0261.12535ca


Files in this item

 
Name:
Ricco Natalia [et al.]_Mevalonate ...
Size:
2.516Mb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record

© 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. 1927. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint